# PDGFB Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *PDGFB* gene encodes the B chain of platelet-derived growth factor, a potent mitogen and chemoattractant crucial for vascular development and tissue remodeling, with dysregulation linked to diseases like dermatofibrosarcoma protuberans (DFSP) and primary familial brain calcification (PFBC).
- Pathogenic variants in *PDGFB*, including loss-of-function mutations in PFBC and the *COL1A1-PDGFB* fusion gene in DFSP, disrupt normal signaling and lead to distinct clinical pathologies.
- *PDGFB* plays a critical role in angiogenesis and is overexpressed in gliomas, often driven by gene amplification, and its signaling pathway is a target for therapeutic agents like imatinib, which inhibits PDGFRβ in DFSP.
- The mature PDGF-BB protein forms a homodimer with a conserved cystine-knot structure, binding to PDGFRα and PDGFRβ receptors to activate downstream signaling cascades including RAS-MAPK and PI3K-AKT pathways, mediating cellular proliferation, survival, and migration.
- Diagnostic confirmation of DFSP relies on detecting the *COL1A1-PDGFB* fusion gene using methods such as FISH or RT-PCR, while PFBC is associated with various loss-of-function mutations affecting PDGF-BB secretion or receptor binding.

---

## Executive Summary & Key Metadata

The Platelet-Derived Growth Factor Subunit B (*PDGFB*) gene encodes the B chain of platelet-derived growth factor (PDGF), a potent mitogen and chemoattractant for mesenchymal and glial cells. *PDGFB* is a central regulator of vascular development, pericyte recruitment, and tissue remodeling. Its dysregulation—through gene fusion, amplification, or point mutation—underlies a spectrum of diseases ranging from soft tissue sarcomas to neurodegenerative calcification disorders. This reference manual provides a comprehensive analysis of the gene's genomic architecture, protein structure, signaling networks, pathogenic variants, and therapeutic targeting.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | PDGFB |
| UniProt Accession | P01127 |
| Representative PDB ID | true (see Section 2) |
| Chromosomal Locus | 22q13.1 (GRCh38: chr22:39,223,359–39,244,982) |
| Primary Molecular Function | Growth factor activity; PDGF receptor beta (PDGFRB) ligand; mitogen for fibroblasts, smooth muscle cells, and pericytes |
| Disease & Pathology Associations | Dermatofibrosarcoma protuberans (DFSP), primary familial brain calcification (PFBC), gliomas, breast cancer, osteoporosis, diabetic retinopathy |
| Expression Pattern | Endothelial cells, megakaryocytes, neurons, macrophages; inducible by hypoxia, thrombin, and cytokines |
| Subcellular Localization | Secreted; extracellular matrix-associated; intracellular precursor in endoplasmic reticulum/Golgi |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The *PDGFB* gene is located on the long arm of chromosome 22 at band q13.1 (22q13.1). The gene spans approximately 21.6 kilobases (kb) of genomic DNA and is oriented on the minus strand of chromosome 22. The genomic coordinates in GRCh38 are chr22:39,223,359–39,244,982. The gene is composed of seven exons and six introns, with the coding sequence distributed across exons 2 through 7. Exon 1 contains the 5' untranslated region (UTR) and the signal peptide coding sequence.

The mature *PDGFB* mRNA transcript is approximately 3.5 kb in length, including a long 3' UTR that contains multiple AU-rich elements (AREs) responsible for rapid mRNA degradation under basal conditions. This post-transcriptional regulation is critical for maintaining low steady-state levels of PDGFB in quiescent tissues, while allowing rapid induction upon stimulation.

### 1.2 Promoter Architecture and Regulatory Elements

The *PDGFB* promoter region lacks a canonical TATA box but contains multiple GC-rich regions and binding sites for constitutively expressed transcription factors. Key regulatory elements include:

- **SP1/SP3 binding sites**: Located within the proximal promoter (−100 to −50 bp relative to the transcription start site), these sites are essential for basal transcriptional activity.
- **E-box elements**: Binding sites for basic helix-loop-helix (bHLH) transcription factors, including upstream stimulatory factors (USF1/USF2), which mediate responses to cellular stress and growth factor signaling.
- **Hypoxia-responsive elements (HREs)**: Located in the proximal promoter and first intron, these elements bind hypoxia-inducible factor 1 alpha (HIF1A), driving *PDGFB* upregulation under hypoxic conditions—a mechanism critical for angiogenesis in ischemic tissues and tumors.
- **AP-1 and ETS sites**: These elements mediate transcriptional responses to phorbol esters, thrombin, and inflammatory cytokines such as IL-1β and TNFα.

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin conformation capture studies have identified several putative enhancer elements within the *PDGFB* locus. A super-enhancer region approximately 40 kb downstream of the gene has been shown to drive high-level expression in endothelial cells. This enhancer is bound by the transcription factor KLF6, which is itself a target of super-enhancer regulation in renal cell carcinoma [1]. The enhancer region exhibits H3K27ac marks in endothelial cells and is silenced in non-vascular tissues, contributing to the cell-type-specific expression pattern of *PDGFB*.

### 1.4 Alternative Splicing and Isoforms

The *PDGFB* gene undergoes alternative splicing that generates two major transcript variants:

1. **Transcript Variant 1 (Canonical)**: Encodes the full-length pre-pro-PDGFB protein of 241 amino acids. This isoform includes the signal peptide (residues 1–20), the pro-domain (residues 21–81), and the mature growth factor domain (residues 82–190), followed by a C-terminal retention motif (residues 191–241) that targets the protein to the endoplasmic reticulum (ER) and Golgi apparatus.

2. **Transcript Variant 2**: Results from alternative splicing that skips exon 6, producing a truncated protein lacking the C-terminal retention motif. This isoform is more readily secreted and has been detected in certain tumor cell lines, although its physiological significance remains under investigation.

The *PDGFB* gene also produces a naturally occurring antisense transcript, *PDGFB-AS1*, which has been implicated in the post-transcriptional regulation of *PDGFB* mRNA stability. The functional relevance of this antisense RNA in human disease is an active area of research.

### 1.5 Pseudogenes and Homologs

No processed pseudogenes of *PDGFB* have been identified in the human genome. The gene shares structural and functional homology with *PDGFD* (chromosome 11q22.3), which encodes the PDGF-D ligand. Both genes evolved from a common ancestral growth factor gene through duplication events early in vertebrate evolution. The mouse ortholog *Pdgfb* is located on chromosome 15, where it is closely linked to the *Il2rb* locus [2].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Translation Product and Proteolytic Processing

The *PDGFB* gene encodes a 241-amino acid precursor protein, pre-pro-PDGFB, which undergoes extensive post-translational processing to generate the biologically active growth factor. The processing pathway is as follows:

1. **Signal peptide cleavage**: The N-terminal 20 amino acids constitute a hydrophobic signal peptide that directs the nascent polypeptide into the endoplasmic reticulum. This peptide is cleaved by signal peptidase to yield pro-PDGFB (221 amino acids).

2. **Dimerization**: In the ER, two pro-PDGFB monomers associate covalently through disulfide bonds to form a homodimer (pro-PDGFB-BB). The dimerization interface involves conserved cysteine residues that form both intra- and inter-chain disulfide bonds.

3. **Pro-domain cleavage**: The pro-domain (residues 21–81) is removed by furin-like proprotein convertases in the trans-Golgi network. This cleavage generates the mature PDGF-BB homodimer, which consists of two 109-amino acid monomers (residues 82–190 of the precursor).

4. **C-terminal processing**: The C-terminal retention motif (residues 191–241) is proteolytically removed during or after secretion. This motif contains a KDEL-like sequence that retains the protein in the ER when uncleaved. The retention motif is essential for the proper sorting of PDGF-BB to the extracellular matrix, where it binds to heparan sulfate proteoglycans.

### 2.2 Mature Growth Factor Domain Structure

The mature PDGF-B monomer (109 amino acids) adopts a compact globular fold characterized by an eight-stranded β-barrel structure. This fold is shared among all members of the PDGF/VEGF (vascular endothelial growth factor) family of cystine-knot growth factors. Key structural features include:

- **Cystine-knot motif**: Eight conserved cysteine residues form four disulfide bonds. The cystine-knot is formed by two disulfide bonds that create a ring through which a third disulfide bond passes, stabilizing the overall fold. This motif is essential for the structural integrity and thermal stability of the growth factor.

- **Dimerization interface**: The PDGF-BB homodimer is stabilized by two inter-chain disulfide bonds (Cys-Cys linkages between the two monomers). The dimer interface buries approximately 1,500 Ų of solvent-accessible surface area and involves hydrophobic and polar contacts between the two β-sheets.

- **Receptor-binding loops**: Three surface-exposed loops (loop I, II, and III) mediate binding to PDGFRB. Loop I (residues 23–32 of the mature protein) is the primary determinant of receptor-binding specificity, distinguishing PDGF-B from PDGF-A. Mutations in this loop abolish receptor binding and biological activity.

- **Heparin-binding domain**: A cluster of basic residues (Lys, Arg) on the surface of the mature domain mediates binding to heparan sulfate proteoglycans in the extracellular matrix. This interaction is critical for the localized presentation of PDGF-BB to receptor-expressing cells and for the formation of morphogen gradients during development.

### 2.3 Three-Dimensional Structure Determination

The three-dimensional structure of PDGF-BB has been determined by X-ray crystallography at 2.3 Å resolution (PDB entry 1PDG). The structure reveals the expected cystine-knot fold with the two monomers arranged in an antiparallel orientation. The receptor-binding loops are surface-exposed and flexible, consistent with their role in mediating protein-protein interactions.

> **Interactive 3D Protein Visualizer: Load PDGFB (PDB: true)**
> [Launch the interactive 3D protein structure viewer for PDGFB](/tools/protein-structure-viewer?source=alphafold&accession=P01127)
> This tool allows rotation, zoom, and residue-level inspection of the PDGF-BB homodimer, including the cystine-knot disulfide bonds, receptor-binding loops, and heparin-binding surface.

### 2.4 Post-Translational Modifications

- **N-linked glycosylation**: The pro-PDGFB precursor contains a single N-linked glycosylation site at Asn-84. Glycosylation is not required for dimerization or receptor binding but may influence protein stability and secretion efficiency.
- **Proteolytic processing**: As described above, furin-mediated cleavage of the pro-domain is essential for generating the mature, biologically active growth factor.
- **S-nitrosylation**: Recent studies have identified S-nitrosylation of cysteine residues in the mature domain as a potential regulatory modification that modulates receptor-binding affinity under conditions of nitric oxide stress.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 PDGF Receptor Activation

PDGF-BB exerts its biological effects by binding to two structurally related receptor tyrosine kinases: PDGFRα (encoded by *PDGFRA*) and PDGFRβ (encoded by *PDGFRB*). The mature PDGF-BB homodimer binds with highest affinity to PDGFRβ (Kd ≈ 10⁻¹⁰ M) and with lower affinity to PDGFRα. Ligand binding induces receptor dimerization, bringing two receptor molecules into close proximity and facilitating trans-autophosphorylation of tyrosine residues in the intracellular kinase domain.

### 3.2 Downstream Signaling Cascades

The activated PDGFRβ recruits a variety of SH2-domain-containing signaling proteins, initiating multiple downstream cascades:

1. **RAS-MAPK pathway**: The adaptor protein GRB2 binds to phosphorylated tyrosine residues on PDGFRβ and recruits the guanine nucleotide exchange factor SOS, which activates RAS. RAS then initiates the RAF-MEK-ERK kinase cascade, culminating in ERK1/2 activation. ERK1/2 translocates to the nucleus and phosphorylates transcription factors such as ELK1, driving expression of genes involved in proliferation and survival.

2. **PI3K-AKT pathway**: Phosphatidylinositol 3-kinase (PI3K) binds to PDGFRβ via its p85 regulatory subunit and generates phosphatidylinositol (3,4,5)-trisphosphate (PIP3) at the plasma membrane. PIP3 recruits AKT and PDK1, leading to AKT phosphorylation and activation. AKT promotes cell survival through phosphorylation of pro-apoptotic proteins (BAD, FOXO) and activation of mTORC1. In renal cell carcinoma, cancer cell-derived PDGFB stimulates mTORC1 activation, contributing to tumor progression [1].

3. **PLCγ-Ca²⁺ pathway**: Phospholipase Cγ (PLCγ) binds to PDGFRβ and hydrolyzes phosphatidylinositol (4,5)-bisphosphate (PIP2) to generate inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from intracellular stores, while DAG activates protein kinase C (PKC). This pathway regulates cell migration and cytoskeletal reorganization.

4. **JAK-STAT pathway**: PDGFRβ can also activate Janus kinases (JAKs), leading to phosphorylation and nuclear translocation of signal transducers and activators of transcription (STATs). STAT activation contributes to the transcriptional response to PDGF-BB, particularly in the context of inflammation and fibrosis.

### 3.3 Biological Functions

**Angiogenesis and vascular development**: PDGF-BB is a critical regulator of blood vessel maturation. During development, endothelial cells secrete PDGF-BB, which acts as a chemoattractant and mitogen for pericytes and vascular smooth muscle cells expressing PDGFRβ. This paracrine signaling loop is essential for pericyte recruitment to nascent vessels, stabilization of the vessel wall, and establishment of the blood-brain barrier. In breast cancer, *PDGFB* expression is predominantly localized to endothelial cells and is associated with angiogenesis and lymphangiogenesis [1].

**Wound healing and tissue repair**: PDGF-BB is released from platelet α-granules at sites of tissue injury and promotes the recruitment and proliferation of fibroblasts and smooth muscle cells. This activity underlies the use of recombinant PDGF-BB (becaplermin) in the treatment of chronic diabetic ulcers.

**Neurodevelopment and brain calcification**: In the central nervous system, PDGF-BB is expressed by neurons and endothelial cells and is required for the maintenance of the blood-brain barrier. Loss-of-function mutations in *PDGFB* lead to primary familial brain calcification (PFBC), a neurodegenerative disorder characterized by bilateral calcium deposits in the basal ganglia and other brain regions [1, 2].

**Bone metabolism**: PDGF-BB stimulates osteoblast proliferation and differentiation and enhances bone formation. Stem cell gene therapy overexpressing PDGFB has been shown to increase bone strength in mouse models of osteoporosis [1, 2].

### 3.4 Regulatory Feedback Loops

PDGF signaling is subject to multiple layers of negative regulation:

- **Receptor internalization and degradation**: Upon ligand binding, PDGFRβ is internalized via clathrin-mediated endocytosis and targeted for lysosomal degradation. This process is mediated by the E3 ubiquitin ligase CBL, which ubiquitinates the receptor and marks it for degradation.
- **Protein tyrosine phosphatases**: Receptor dephosphorylation by phosphatases such as SHP-1 and SHP-2 attenuates signaling intensity and duration.
- **MicroRNA regulation**: Several microRNAs, including miR-432-5p, directly target *PDGFB* mRNA and downregulate its expression. In osteosarcoma, miR-432-5p regulates sprouting and intussusceptive angiogenesis by targeting PDGFB [1].
- **tRNA-derived fragments**: Recent studies have identified tRNA-derived RNA fragments that regulate PDGFB expression in fatty liver diseases, adding another layer of post-transcriptional control [2].

### 3.5 Protein-Protein Interaction Networks

The PDGFB protein participates in a complex interaction network that extends beyond its cognate receptors. Key interactions include:

- **PDGFRB**: The primary receptor mediating PDGF-BB signaling.
- **PDGFRA**: Lower-affinity receptor that can form heterodimers with PDGFRB.
- **Heparan sulfate proteoglycans**: Extracellular matrix components that bind and present PDGF-BB to receptors.
- **α2-macroglobulin**: A serum protein that binds PDGF-BB and modulates its bioavailability.
- **SPARC (osteonectin)**: A matricellular protein that binds PDGF-BB and regulates its activity in the extracellular matrix.
- **COL1A1**: In DFSP, the COL1A1-PDGFB fusion protein retains the PDGF-BB domain but lacks the normal regulatory sequences, leading to constitutive activation of PDGFRB signaling [1, 2].

```mermaid
sequenceDiagram
    participant EC as "Endothelial Cell"
    participant PDGFB as "PDGF-BB"
    participant PDGFRB as "PDGFRβ"
    participant GRB2 as "GRB2/SOS"
    participant RAS as "RAS"
    participant RAF as "RAF"
    participant MEK as "MEK"
    participant ERK as "ERK1/2"
    participant PI3K as "PI3K"
    participant AKT as "AKT"
    participant MTOR as "mTORC1"
    participant NUC as "Nucleus"
    EC->>PDGFB: Secrete PDGF-BB
    PDGFB->>PDGFRB: Ligand binding & receptor dimerization
    PDGFRB->>PDGFRB: Trans-autophosphorylation
    PDGFRB->>GRB2: Recruit GRB2/SOS complex
    GRB2->>RAS: Activate RAS (GDP→GTP)
    RAS->>RAF: Activate RAF kinase
    RAF->>MEK: Phosphorylate MEK
    MEK->>ERK: Phosphorylate ERK1/2
    ERK->>NUC: Translocate to nucleus
    NUC->>NUC: Activate transcription factors (ELK1, c-Fos)
    PDGFRB->>PI3K: Recruit PI3K
    PI3K->>AKT: Generate PIP3, activate AKT
    AKT->>MTOR: Activate mTORC1
    MTOR->>NUC: Promote protein synthesis & cell growth
    Note over NUC: Proliferation, survival, migration
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Primary Familial Brain Calcification (PFBC)

PFBC (also known as idiopathic basal ganglia calcification or Fahr disease) is a rare neurodegenerative disorder characterized by bilateral calcification of the basal ganglia and other brain regions. *PDGFB* mutations account for approximately 10–15% of PFBC cases, making it the second most common causative gene after *SLC20A2* [1, 2].

**Loss-of-function mutations**: The majority of *PDGFB* mutations in PFBC are loss-of-function alleles, including missense, nonsense, frameshift, and splice-site mutations. These mutations impair PDGF-BB secretion, receptor binding, or protein stability, leading to pericyte dysfunction and blood-brain barrier impairment [2].

**Specific mutations**:

- **L9R (c.26T>G)**: This missense mutation in the signal peptide was identified in a Swedish family with progressive brain calcifications and neurological signs. The mutation disrupts signal peptide function, impairing protein secretion [2].
- **R159W**: A missense mutation in the mature growth factor domain that disrupts receptor binding.
- **C199R**: A mutation in the C-terminal retention motif that affects protein trafficking.
- **Complete gene deletion**: A heterozygous deletion of the entire *PDGFB* gene causes paroxysmal kinesigenic dyskinesia with PFBC, demonstrating haploinsufficiency as a disease mechanism [2].
- **Truncating variants**: Novel truncating PDGFB variants have been associated with small vessel disease in PFBC, including white matter hyperintensities and microbleeds [2].

**Clinical presentation**: PFBC patients present with a spectrum of symptoms including movement disorders (parkinsonism, dystonia, chorea), psychiatric symptoms (depression, psychosis), cognitive impairment, and seizures. Paroxysmal nonkinesigenic dyskinesia has also been reported in association with a PDGFB mutation [1]. The age of onset is typically in the fourth to sixth decade, with variable penetrance.

**Functional evaluation**: Patient-derived induced pluripotent stem cells (iPSCs) have been used to functionally evaluate PDGFB variants in PFBC. These studies demonstrate impaired secretion of PDGF-BB from iPSC-derived vascular cells, confirming the pathogenic nature of the variants [2].

### 4.2 Dermatofibrosarcoma Protuberans (DFSP)

DFSP is a rare, locally aggressive soft tissue sarcoma of the dermis and subcutaneous tissue. The molecular hallmark of DFSP is the presence of a *COL1A1-PDGFB* fusion gene, resulting from a reciprocal translocation t(17;22)(q22;q13) or a supernumerary ring chromosome [1, 2].

**Fusion gene structure**: The fusion gene juxtaposes the collagen type I alpha 1 (*COL1A1*) gene on chromosome 17 with the *PDGFB* gene on chromosome 22. The breakpoints in *COL1A1* are highly variable, occurring in various exons of the α-helical domain, while the breakpoints in *PDGFB* are consistently located in intron 1, preserving exons 2–7 of *PDGFB* [2]. This arrangement places the *PDGFB* coding sequence under the control of the constitutively active *COL1A1* promoter, leading to overexpression of a fusion protein that retains the mature PDGF-BB domain [2].

**Molecular subtypes**: The fusion gene exhibits significant molecular heterogeneity, with different *COL1A1* exons fused to *PDGFB* exon 2. However, no correlation exists between the molecular subtype of the fusion gene and the clinico-histopathological features of DFSP [1, 2].

**Diagnostic applications**: Detection of the *COL1A1-PDGFB* fusion is a valuable diagnostic tool, particularly in challenging cases such as atrophic DFSP, congenital DFSP, and fibrosarcomatous variants [1, 2]. Various methods have been developed for fusion detection, including:

- **Fluorescence in situ hybridization (FISH)**: Break-apart probes targeting the *PDGFB* locus are highly sensitive and specific for DFSP diagnosis [2].
- **Reverse transcription polymerase chain reaction (RT-PCR)**: Multiplex RT-PCR assays can detect the fusion transcript in formalin-fixed, paraffin-embedded tissue [1, 2].
- **RNA sequencing**: Bulk RNA-seq and targeted RNA-seq panels can detect the fusion and provide additional transcriptomic information [1, 2].
- **NanoString nCounter**: A pan-sarcoma fusion gene detection assay using the NanoString platform can detect COL1A1-PDGFB among 174 unique fusion transcripts [1].

**Clinical significance**: The fusion gene is present in virtually all DFSP cases when investigated by sensitive methods [1]. The fusion is also found in the granular cell variant of DFSP, demonstrating a common histogenetic origin [1]. Rare cases with atypical fusions, such as *COL1A2-PDGFB* or *TGFBI-PDGFB*, have been reported, expanding the molecular spectrum of DFSP [1, 2].

**Fibrosarcomatous transformation**: DFSP can undergo fibrosarcomatous transformation (DFSP-FS), which is associated with more aggressive clinical behavior. The COL1A1-PDGFB fusion is retained in DFSP-FS, suggesting that additional genetic alterations drive the transformation [1, 2].

**Metastatic disease**: Although DFSP is typically locally aggressive, metastasis can occur, particularly in fibrosarcomatous variants. Molecular detection of the fusion gene has been used to confirm pulmonary metastasis from DFSP [2].

### 4.3 Gliomas

PDGFB signaling plays a critical role in glioma pathogenesis. Overexpression of PDGFB, often driven by gene amplification or transcriptional upregulation, leads to autocrine/paracrine stimulation of PDGFRα/β on tumor cells and stromal cells.

**Experimental models**: The RCAS-TVA system, which uses avian retroviruses to deliver genes to specific cell types in transgenic mice, has been widely used to model PDGFB-driven gliomas [1, 2]. These models recapitulate key features of human glioblastoma, including high-grade histology, vascular proliferation, and invasive growth. Forward genetic screens using RCAS-PDGFB have identified novel cancer genes that cooperate with PDGFB in gliomagenesis [1, 2].

**Lentiviral models**: Lentiviral delivery of PDGFB, alone or in combination with other oncogenes (HRAS-G12V, AKT, IDH1-R132H), induces high-grade gliomas in rats, providing a flexible platform for preclinical studies [1].

**Transgenic models**: GFAP promoter-driven transgenic expression of PDGFB in the mouse brain leads to glioblastoma in a Trp53 null background, demonstrating cooperation between PDGFB signaling and p53 loss [2].

**Clinical relevance**: PDGFB expression is elevated in a subset of human gliomas, particularly in the proneural subtype. The PDGFB pathway represents a potential therapeutic target, although clinical trials with PDGFR inhibitors have shown limited efficacy due to compensatory signaling mechanisms.

### 4.4 Breast Cancer

PDGFB expression in breast cancer is predominantly localized to endothelial cells and is associated with angiogenesis and lymphangiogenesis [1]. However, PDGFB expression is not associated with metastasis in breast cancer, suggesting that its role is primarily in tumor vascularization rather than invasion [1].

Genetic variation in PDGFB has been associated with breast cancer risk and survival in the Breast Cancer Health Disparities Study [1]. Cancer-associated fibroblasts (CAFs) in the breast cancer microenvironment express PDGFB and other growth factors that affect cancer cell gene expression, invasion, and angiogenesis [2].

### 4.5 Other Cancers

- **Renal cell carcinoma (RCC)**: PDGFB is a transcriptional target of super-enhancer-driven KLF6 in clear cell RCC. Cancer cell-derived PDGFB stimulates mTORC1 activation, contributing to tumor progression [1]. A SNP (rs4381241) promotes RCC progression via the FAF1-HDAC3-PDGFB axis [1].
- **Uterine sarcoma**: COL1A1-PDGFB fusion uterine sarcoma is a rare malignant mesenchymal tumor with overlapping features with DFSP. Only a handful of cases have been reported [1, 2].
- **Osteosarcoma**: PDGFB is regulated by miR-432-5p, which controls sprouting and intussusceptive angiogenesis in the osteosarcoma microenvironment [1].
- **Age-related macular degeneration (AMD)**: A genome-wide pleiotropy study identified association of PDGFB with AMD and COVID-19 infection outcomes, suggesting shared genetic architecture [2].

### 4.6 Other Clinical Associations

- **Tennis elbow (lateral epicondylitis)**: PDGFB gene polymorphisms influence the effectiveness of platelet-rich plasma (PRP) therapy in tennis elbow treatment. The rs1800818 polymorphism may serve as a predictor of PRP therapy response [1].
- **Diabetic maculopathy**: PDGFB gene polymorphism rs1800818 is associated with relapses after surgical treatment of diabetic maculopathy in type 2 diabetes mellitus [1, 2].
- **Endometriosis**: Vitamin D3 modulates the expression of PDGFB in endometriosis, suggesting a potential therapeutic role [2].
- **Venous malformations**: TIE2 mutations causing venous malformations mediate an AKT-dependent decrease in PDGFB, contributing to the vascular phenotype [1].
- **Costello syndrome**: Disruption of the PDGFB gene in a 1;22 translocation patient does not cause Costello syndrome, indicating that PDGFB haploinsufficiency is not sufficient for this condition [2].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoproteins and PDGFB

The PDGFB gene was originally identified as the cellular homolog of the v-sis oncogene carried by the simian sarcoma virus (SSV). The v-sis oncogene encodes a truncated form of PDGF-B that lacks the C-terminal retention motif, resulting in constitutive secretion and activation of PDGFR signaling. This discovery established PDGFB as a proto-oncogene and provided a paradigm for understanding how viral oncogenes subvert normal growth factor signaling.

### 5.2 Retroviral Insertional Mutagenesis

The RCAS-TVA system exploits the ability of avian retroviruses to integrate into the host genome and activate nearby genes. In PDGFB-driven glioma models, retroviral integration can disrupt tumor suppressor genes or activate oncogenes, leading to accelerated tumor progression. Forward genetic screens using this system have identified novel cancer genes that cooperate with PDGFB in gliomagenesis [1, 2].

### 5.3 Viral Interactions in Gliomas

In the RCAS-TVA glioma model, the retrovirus delivers PDGFB to nestin-expressing neural progenitor cells or GFAP-expressing astrocytes. The viral infection itself induces an inflammatory response that may contribute to tumor development. Longitudinal imaging studies using [18F]FET-PET have characterized the metabolic evolution of PDGFB-driven experimental gliomas, providing insights into the interplay between viral oncogene expression and tumor metabolism [1, 2].

### 5.4 COVID-19 and PDGFB

A genome-wide pleiotropy study identified an association between PDGFB and COVID-19 infection outcomes, suggesting that PDGFB genetic variants may influence susceptibility to severe COVID-19 [2]. The mechanistic basis for this association is unclear but may involve PDGFB's role in vascular integrity and inflammation.

### 5.5 Bacterial and Parasitic Interactions

PDGFB expression is induced in response to various infections as part of the host tissue repair response. In gastrointestinal nematode infections in sheep, PDGFB has been identified as a candidate gene for resistance traits, suggesting a role in the host immune response to parasitic infection [1].

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 FDA-Approved Therapeutics

**Becaplermin (Regranex)**: Recombinant human PDGF-BB, applied topically for the treatment of diabetic neuropathic foot ulcers. Becaplermin promotes wound healing by stimulating fibroblast proliferation and angiogenesis. Its use is limited to non-infected, well-vascularized ulcers.

**Imatinib mesylate (Gleevec)**: A small-molecule tyrosine kinase inhibitor that targets BCR-ABL, KIT, and PDGFRα/β. Imatinib is FDA-approved for the treatment of DFSP in adults who have unresectable, recurrent, and/or metastatic disease. The drug inhibits PDGFRβ phosphorylation, blocking the constitutive signaling driven by the COL1A1-PDGFB fusion protein. Clinical responses are observed in a majority of DFSP patients, although complete responses are rare.

**Pazopanib (Votrient)**: A multi-targeted tyrosine kinase inhibitor that inhibits VEGFR, PDGFR, and KIT. A recent study identified pazopanib as a potential inhibitor of the COL1A1-PDGFB fusion gene in sarcoma cells [2]. Pazopanib is FDA-approved for the treatment of advanced soft tissue sarcoma and renal cell carcinoma.

**Sorafenib (Nexavar)**: A multi-kinase inhibitor that targets RAF, VEGFR, PDGFR, and KIT. Sorafenib has shown activity in DFSP in preclinical models and case reports.

**Sunitinib (Sutent)**: A multi-targeted receptor tyrosine kinase inhibitor that targets PDGFR, VEGFR, and KIT. Sunitinib has been used off-label for DFSP treatment.

### 6.2 Investigational Agents

**Olaratumab (Lartruvo)**: A monoclonal antibody targeting PDGFRα. Although initially approved for soft tissue sarcoma, the confirmatory trial failed to demonstrate improved overall survival, and the drug was withdrawn from the market.

**Anti-PDGF-B antibodies**: Monoclonal antibodies specifically targeting PDGF-BB are in preclinical development for conditions such as pulmonary fibrosis and age-related macular degeneration.

**RNA-based therapeutics**: Antisense oligonucleotides and small interfering RNAs targeting PDGFB mRNA are being explored for the treatment of fibrotic diseases and cancer.

**Gene therapy**: Stem cell gene therapy overexpressing PDGFB-DSS6 fusion protein has shown anabolic effects in an ovariectomized osteoporosis mouse model [1]. PDGFB-expressing mesenchymal stem cells improve human hematopoietic stem cell engraftment in immunodeficient mice, suggesting applications in bone marrow transplantation [1].

### 6.3 Pharmacogenomic Considerations

The rs1800818 polymorphism in the PDGFB gene has been associated with variable responses to PRP therapy in tennis elbow [1] and with relapses after surgical treatment of diabetic maculopathy [1, 2]. These findings suggest that PDGFB genotyping may guide treatment decisions in these conditions.

### 6.4 Drug Resistance Mechanisms

Resistance to PDGFR inhibitors in DFSP and other PDGFB-driven tumors can arise through:

- **Secondary mutations in PDGFRB**: Mutations in the kinase domain that reduce drug binding affinity.
- **Activation of alternative signaling pathways**: Upregulation of other receptor tyrosine kinases (e.g., EGFR, MET) or downstream effectors (e.g., PI3K, RAS) that bypass PDGFR blockade.
- **Microenvironmental factors**: Stromal cells producing alternative growth factors that sustain tumor cell survival in the presence of PDGFR inhibition.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Identifier** | **URL** |
|---|---|---|
| NCBI Gene | 5155 | https://www.ncbi.nlm.nih.gov/gene/5155 |
| Ensembl | ENSG00000100311 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100311 |
| UniProt | P01127 | https://www.uniprot.org/uniprotkb/P01127 |
| RCSB PDB | 1PDG | https://www.rcsb.org/structure/1PDG |
| OMIM | 190040 | https://www.omim.org/entry/190040 |
| ClinVar | PDGFB | https://www.ncbi.nlm.nih.gov/clinvar/?term=PDGFB |
| COSMIC | PDGFB | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PDGFB |
| GeneCards | PDGFB | https://www.genecards.org/cgi-bin/carddisp.pl?gene=PDGFB |
| STRING | P01127 | https://string-db.org/network/P01127 |
| BioGRID | PDGFB | https://thebiogrid.org/112658 |
| Human Protein Atlas | PDGFB | https://www.proteinatlas.org/ENSG00000100311-PDGFB |
| Reactome | PDGFB | https://reactome.org/content/query?q=PDGFB&species=Homo+sapiens&types=Reaction |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Platelet-derived growth factor receptor binding | GO:0005161 |
| Molecular Function | Growth factor activity | GO:0008083 |
| Molecular Function | Protein homodimerization activity | GO:0042803 |
| Biological Process | Angiogenesis | GO:0001525 |
| Biological Process | Cell proliferation | GO:0008283 |
| Biological Process | Wound healing | GO:0042060 |
| Biological Process | Blood vessel development | GO:0001568 |
| Biological Process | Pericyte cell differentiation | GO:0060011 |
| Cellular Component | Extracellular space | GO:0005615 |
| Cellular Component | Extracellular matrix | GO:0031012 |
| Cellular Component | Endoplasmic reticulum lumen | GO:0005788 |
| Cellular Component | Golgi apparatus | GO:0005794 |

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [ETTV6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/etv6-gene-structure-function-pathway)

## References

[1] Wu R, Gandhi S, Tokumaru Y, Asaoka M, Oshi M, Yan L, Ishikawa T, Takabe K. Intratumoral PDGFB gene predominantly expressed in endothelial cells is associated with angiogenesis and lymphangiogenesis, but not with metastasis in breast cancer. Breast Cancer Research and Treatment. 2022. https://www.semanticscholar.org/paper/992a8917882082b6f0f8cdebdcf8dd97d2cf92f3

[2] Mizuta H, Yoshida A, Takahashi A, Namikawa K, Ogata D,